Hermine I. Brunner, MD, MSc, MBA

Director, Division of Rheumatology

Professor, UC Department of Pediatrics

Phone 513-636-6320

Fax 513-636-4116

Email hermine.brunner@cchmc.org


Health-related quality of life; outcome research; lupus


Economic analyses; HRQOL; measurement development; outcome research; lupus 

Visit the Brunner Lab.

Hermine Brunner, MD, MSc, MBA, is a pediatric rheumatologist with a special clinical and research interest in pediatric lupus. Her research is focused on biomarker discovery and the testing of new medications for lupus. She is also involved in trial design and provides statistical support at Cincinnati Children's. As head of the Lupus Center, she is involved in the conduction of the Lupus Clinic and the organization of Lupus Support Groups. She also pioneers the development of outcome measures and improving the quality of clinical of children with lupus and other rheumatic diseases.

MD: Ludwig Maximilan University, Munich, Germany, 1991.

Residency: University of Chicago, 1997.

Fellowship: University of Toronto & Cincinnati, 1999.

MSc: Clinical Epidemiology: University of Toronto, 1999.

Certification: Pediatrics 1997; Rheumatology, 2002.

View PubMed Publications

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. New England Journal of Medicine. 2012;367(25):2396-406.

Ross GS, Zelko F, Klein-Gitelman M, Levy DM, Muscal E, Schanberg LE, Anthony K, Brunner HI. A proposed framework to standardize the neurocognitive assessment of patients with pediatric systemic lupus erythematosus. Arthritis care & research. 2010;62(7):1029-33.

De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. New England Journal of Medicine. 2012;367(25):2385-95.

Brunner HI, Silva CA, Reiff A, Higgins GC, Imundo L, Williams CB, Wallace CA, Aikawa NE, Nelson S, Klein-Gitelman MS, Rose SR. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(5):1377-85.

Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A, Mishra J, Devarajan P. Urinary neutrophil gelatinase–associated lipocalin as a biomarker of nephritis in childhood‐onset systemic lupus erythematosus. Arthritis & Rheumatism. 2006;54(8):2577-84.

Brunner HI, Klein-Gitelman MS, Zelko F, Thomas EC, Hummel J, Nelson SM, Huggins J, Curran ML, Roebuck-Spencer T, Beebe DW, Ying J. Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus. Arthritis care & research. 2013;65(3):372-81.

Brunner HI, Klein-Gitelman MS, Higgins GC, Lapidus SK, Levy DM, Eberhard A, Singer N, Olson JC, Onel K, Punaro M, Schanberg L, von Scheven E, Ying J, Giannini EH. Toward the Development of Criteria for Global Flares in Juvenile Systemic Lupus Erythematosus. Arthritis care & research. 2010;62(6):811-20.

Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood‐onset and adult‐onset systemic lupus erythematosus. Arthritis & Rheumatism. 2008;58(2):556-62.

Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD. The diagnostic significance of soluble CD163 and soluble interleukin‐2 receptor α‐chain in macrophage activation syndrome and untreated new‐onset systemic juvenile idiopathic arthritis. Arthritis & Rheumatism. 2007;56(3):965-71.

DiFrancesco MW, Holland SK, Ris MD, Adler CM, Nelson S, DelBello MP, Altaye M, Brunner HI. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. Arthritis and rheumatism. 2007;56(12):4151-63.